Lorenzo Moja

Lorenzo Moja

Auto-generated profile, based on publicly available information

Lorenzo Moja

Health Products Policy and Standards, World Health Organization, Geneva, Switzerland

Research Focus & Metrics

Academic Career Length

24Years (2003-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2008 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
SDSilvia Deandrea
Silvia Deandrea
MMM. Montanari
M. Montanari
LML. Moja
L. Moja
GAG. Apolone
G. Apolone
Background: Pain is a major health care problem for patients with cancer: despite the existence of guidelines for cancer pain management, undertreatment is a widespread problem. Pain Management Indexes (PMIs) evaluate the congruence between the patient's reported level of pain and the intensity/strength of the analgesic therapy. Negative scores indicate inadequate prescriptions. Materials and methods: We conducted a Medline search using terms for ‘pain management’, ‘index’ or ‘measure’ to select studies which measured undertreatment in cancer settings. Univariate and multivariate logistic regression identified associations between independent predictors and high prevalence of undertreatment. Results: Among the 44 studies identified, 26 studies used the PMI as proposed by Cleeland. The range of negative PMI varied from 8% to 82% with a weighted mean value of 43%. In multivariate analyses, factors associated with negative PMI were date of publication before 2001, provenance from Europe or Asia and countries with a gross national income per capita <$40 000 per year and a care setting not specific for cancer. Age was not a significant predictor for undertreatment. Conclusion: Nearly one of two patients with cancer pain is undertreated. The percentage is high, but consists of a large variability of undertreatment across studies and settings.

3 October 2012 in PLOS ONE
Verified
Journal Article
Open access
PDF file
LMLorenzo Moja
Lorenzo Moja
APAlessandra Piatti
Alessandra Piatti
VPValentina Pecoraro
Valentina Pecoraro
Cristian RicciCristian Ricci
Cristian Ricci
GVGianni Virgili
Gianni Virgili
Giuseppe BanfiGiuseppe Banfi
Giuseppe Banfi
To assess the relationship between surgical delay and mortality in elderly patients with hip fracture. Systematic review and meta-analysis of retrospective and prospective studies published from 1948 to 2011. Medline (from 1948), Embase (from 1974) and CINAHL (from 1982), and the Cochrane Library. Odds ratios (OR) and 95% confidence intervals for each study were extracted and pooled with a random effects model. Heterogeneity, publication bias, Bayesian analysis, and meta-regression analyses were done. Criteria for inclusion were retro- and prospective elderly population studies, patients with operated hip fractures, indication of timing of surgery and survival status. There were 35 independent studies, with 191,873 participants and 34,448 deaths. The majority considered a cut-off between 24 and 48 hours. Early hip surgery was associated with a lower risk of death (pooled odds ratio (OR) 0.74, 95% confidence interval (CI) 0.67 to 0.81; P<0.000) and pressure sores (0.48, 95% CI 0.38 to 0.60; P<0.000). Meta-analysis of the adjusted prospective studies gave similar results. The Bayesian probability predicted that about 20% of future studies might find that early surgery is not beneficial for decreasing mortality. None of the confounders (e.g. age, sex, data source, baseline risk, cut-off points, study location, quality and year) explained the differences between studies. Surgical delay is associated with a significant increase in the risk of death and pressure sores. Conservative timing strategies should be avoided. Orthopaedic surgery services should ensure the majority of patients are operated within one or two days.

1 November 2020 in Science of The Total Environment
Verified
Journal Article
Closed access
SRSara Giordana Rimoldi
Sara Giordana Rimoldi
FSFabrizio Stefani
Fabrizio Stefani
AGAnna Gigantiello
Anna Gigantiello
STEFANO POLESELLOSTEFANO POLESELLO
STEFANO POLESELLO
FCFrancesco Comandatore
Francesco Comandatore
FSFranco Salerno
Franco Salerno

12 March 2014 in JAMA
Verified
Journal Article
Open access
PDF file
BKBenjamin Kasenda
Benjamin Kasenda
EEErik von Elm
Erik von Elm
JYJohn You
John You
ABAnette Blümle
Anette Blümle
YTYuki Tomonaga
Yuki Tomonaga
MBMatthias Briel
Matthias Briel
Conducting high-quality randomized clinical trials (RCTs) is challenging and resource-demanding. Trials are often not conducted as planned or are even prematurely discontinued, eg, for reasons of unexpected harm from the intervention, early superiority, futility, administrative problems, or poor recruitment of participants. Trial discontinuation poses ethical concerns, particularly if results remain unreported, and may represent a considerable waste of scarce research resources.1-3

18 April 2012 in Cochrane Database of Systematic Reviews
Verified
Journal Article
Closed access
PDF file
LMLorenzo Moja
Lorenzo Moja
LTLudovica Tagliabue
Ludovica Tagliabue
SBSara Balduzzi
Sara Balduzzi
EPElena Parmelli
Elena Parmelli
VPVanna Pistotti
Vanna Pistotti
RDRoberto D‘Amico
Roberto D‘Amico

1 December 2014 in American Journal of Public Health
Verified
Journal Article
Closed access
LMLorenzo Moja
Lorenzo Moja
KKKoren H. Kwag
Koren H. Kwag
TLTheodore Lytras
Theodore Lytras
LBLorenzo Bertizzolo
Lorenzo Bertizzolo
LBLinn Brandt
Linn Brandt
Stefanos BonovasStefanos Bonovas
Stefanos Bonovas
We systematically reviewed randomized controlled trials (RCTs) assessing the effectiveness of computerized decision support systems (CDSSs) featuring rule- or algorithm-based software integrated with electronic health records (EHRs) and evidence-based knowledge. We searched MEDLINE, EMBASE, Cochrane Central Register of Controlled Trials, and Cochrane Database of Abstracts of Reviews of Effects. Information on system design, capabilities, acquisition, implementation context, and effects on mortality, morbidity, and economic outcomes were extracted. Twenty-eight RCTs were included. CDSS use did not affect mortality (16 trials, 37395 patients; 2282 deaths; risk ratio [RR] = 0.96; 95% confidence interval [CI] = 0.85, 1.08; I2 = 41%). A statistically significant effect was evident in the prevention of morbidity, any disease (9 RCTs; 13868 patients; RR = 0.82; 95% CI = 0.68, 0.99; I2 = 64%), but selective outcome reporting or publication bias cannot be excluded. We observed differences for costs and health service utilization, although these were often small in magnitude. Across clinical settings, new generation CDSSs integrated with EHRs do not affect mortality and might moderately improve morbidity outcomes.